Immunologic and nonimmunologic sclerodermal skin conditions - review
暂无分享,去创建一个
A. Tatu | Mihaela Crăescu | Carmen Bobeica | C. Tiutiuca | M. Debita | M. Miulescu | A. Pelin | Gabriela Bălan | A. Nicolescu | Elena-Laura Parapiru | E. Niculeț | C. I. Vasile | Andreea Mioara Corduneanu-Luca | C. Vasile | Mihaela Craescu
[1] G. Nuovo,et al. Lichen sclerosus: A C5B-9 mediated chronic microvascular injury syndrome potentially reflective of common adult comorbidities. , 2022, Annals of diagnostic pathology.
[2] A. Tatu,et al. Interrelationship and Sequencing of Interleukins4, 13, 31, and 33 – An Integrated Systematic Review: Dermatological and Multidisciplinary Perspectives , 2022, Journal of inflammation research.
[3] A. Tatu,et al. New Antifibroblastic Medication in Dermatology: Could Nintedanib Treat Scarring? , 2022, International journal of general medicine.
[4] A. Tatu,et al. CREST Syndrome in Systemic Sclerosis Patients – Is Dystrophic Calcinosis a Key Element to a Positive Diagnosis? , 2022, Journal of inflammation research.
[5] A. Tatu,et al. Hearing Loss Secondary to Systemic Sclerosis Vasculopathy: Case Study with a Short Review , 2022, Clinical, cosmetic and investigational dermatology.
[6] V. Wiwanitkit,et al. Morphea and COVID‐19 mRNA vaccine , 2022, International journal of dermatology.
[7] T. Krieg,et al. Pathophysiology of systemic sclerosis (scleroderma) , 2022, The Kaohsiung journal of medical sciences.
[8] D. Brǎnișteanu,et al. Mucocutaneous lesions associated with SARS-CoV-2 infection (Review) , 2022, Experimental and therapeutic medicine.
[9] S. Dash,et al. Puckered chin sign in systemic sclerosis. , 2022, Journal of the American Academy of Dermatology.
[10] P. Celepli,et al. A case of morphea following the COVID‐19 mRNA vaccine: on the basis of viral spike proteins , 2022, International journal of dermatology.
[11] A. Tatu,et al. Diagnostic and Management of Undescended Ovary – A Preoperative Dilemma: A Case-Based Systematic Review , 2022, International journal of women's health.
[12] D. Brǎnișteanu,et al. Metabolic comorbidities of psoriasis (Review) , 2021, Experimental and therapeutic medicine.
[13] I. Patoulias,et al. Balanitis Xerotica Obliterans:an underestimated cause of secondary phimosis. , 2021, Folia medica Cracoviensia.
[14] D. Iordan,et al. Age-Related, Sport-Specific Dysfunctions of the Shoulder and Pelvic Girdle in Athletes Table Tennis Players. Observational Study , 2021, Balneo and PRM Research Journal.
[15] L. Mititelu-Tarțău,et al. The Analysis of Chitosan-Coated Nanovesicles Containing Erythromycin—Characterization and Biocompatibility in Mice , 2021, Antibiotics.
[16] L. Rebegea,et al. Basal cell carcinoma: Comprehensive clinical and histopathological aspects, novel imaging tools and therapeutic approaches (Review) , 2021, Experimental and therapeutic medicine.
[17] A. Nicolescu. MIMOSA TENUIFLORA FOR THE TREATMENT OF DAMAGED SKIN – STUDY ON ITS EFFICACY AND TOLERABILITY IN THE TREATMENT OF IRRITATIVE CONTACT DERMATITIS , 2021, FARMACIA.
[18] Mihaela Crăescu,et al. Predictive value of immunological markers in systemic sclerosis , 2021, Experimental and therapeutic medicine.
[19] M. Miulescu,et al. An Unusual Case of Meckel Diverticulitis Misdiagnosed as an Infected Urachal Cyst , 2021, Medicina.
[20] S. Arias-Santiago,et al. Frontal Fibrosing Alopecia: A Review , 2021, Journal of clinical medicine.
[21] E. Lazaridou,et al. Scleredema diabeticorum – A case report , 2021, Journal of family medicine and primary care.
[22] A. Tatu,et al. Multifactorial expression of IL-6 with update on COVID-19 and the therapeutic strategies of its blockade (Review) , 2021, Experimental and therapeutic medicine.
[23] A. Tatu,et al. Glucocorticoid-Induced Skin Atrophy: The Old and the New , 2020, Clinical, cosmetic and investigational dermatology.
[24] I. Gnanasekaran,et al. Nephrogenic Systemic Fibrosis. , 2020, The American journal of the medical sciences.
[25] R. Haber,et al. Scleromyxedema treatment: a systematic review and update , 2020, International journal of dermatology.
[26] A. Stoian,et al. Treatment of lipomas and diffuse lipomatosis with NDYAG 1064 NM laser and their impact on the quality of life , 2020 .
[27] G. Amarilyo,et al. Systemic Sclerosis Sine Scleroderma With Pulmonary Arterial Hypertension in a 3-Year-Old Girl , 2020, Pediatrics.
[28] T. Krieg,et al. Versorgungsrealität der stationären vasoaktiven Therapie mit Prostazyklinderivaten bei Patienten mit akralen Durchblutungsstörungen bei systemischer Sklerose in Deutschland , 2020, Zeitschrift für Rheumatologie.
[29] B. Breyer,et al. Pathophysiology, Clinical Manifestations, and Treatment of Lichen Sclerosus: a systematic review. , 2020, Urology.
[30] C. Preda,et al. CBCT Evaluation of the Mandibular Bone Quality in Relation to Skeletal Status After Treatment with Strontium Renelate in Diabetic Patients , 2019, Revista de Chimie.
[31] A. Holland,et al. Balanitis xerotica obliterans: an update for clinicians , 2019, European Journal of Pediatrics.
[32] H. Miot,et al. Case for diagnosis. Sclerodermiform manifestations of porphyria cutanea tarda secondary to hepatitis C* , 2019, Anais brasileiros de dermatologia.
[33] H. Ihn. Eosinophilic fasciitis: From pathophysiology to treatment. , 2019, Allergology international : official journal of the Japanese Society of Allergology.
[34] C. Antinozzi,et al. Exosomes in Systemic Sclerosis: Messengers Between Immune, Vascular and Fibrotic Components? , 2019, International journal of molecular sciences.
[35] A. Della Rossa,et al. One year in review 2019: systemic sclerosis. , 2019, Clinical and experimental rheumatology.
[36] I. Sharawat,et al. Multiple sites acquired lipodystrophy in two siblings: a rare adverse effect of intramuscular triamcinolone , 2019, BMJ Case Reports.
[37] T. Rodríguez-Reyna,et al. Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast , 2019, BioMed research international.
[38] A. Tatu,et al. Statins. A Review on Structural Perspectives, Adverse Reactions and Relations with Non-melanoma Skin Cancer , 2018, Revista de Chimie.
[39] Saxon D. Smith,et al. Balanitis xerotica obliterans: a review of diagnosis and management , 2018, International journal of dermatology.
[40] Male genital lichen sclerosus—a permanent therapeutic challenge , 2018, Journal of the American Academy of Dermatology.
[41] M. Viggiano,et al. The challenge of pet therapy in systemic sclerosis: evidence for an impact on pain, anxiety, neuroticism and social interaction. , 2018, Clinical and experimental rheumatology.
[42] L. Benzekri,et al. Association rare: lichen scléroatrophique extragénital et vitiligo inflammatoire chez un enfant , 2018, The Pan African Medical Journal.
[43] P. Elsner,et al. Treatment of Scleroedema Adultorum Buschke: A Systematic Review. , 2018, Acta dermato-venereologica.
[44] P. Losty,et al. Does application of topical steroids for lichen sclerosus (balanitis xerotica obliterans) affect the rate of circumcision? A systematic review. , 2018, Journal of pediatric surgery.
[45] Tammara A. Wood,et al. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis , 2018, Arthritis & rheumatology.
[46] Z. Amoura,et al. [Cancers associated with systemic sclerosis involving anti-RNA polymerase III antibodies]. , 2017, Annales de dermatologie et de venereologie.
[47] I. Sharawat,et al. Localized Lipodystrophy following Single Dose Intramuscular Gentamycin Injection , 2017, Indian dermatology online journal.
[48] A. Tatu,et al. Pityriasis Folliculorum of the Back Thoracic Area: Pityrosporum, Keratin Plugs, or Demodex Involved? , 2017, Journal of cutaneous medicine and surgery.
[49] S. Aytekin,et al. A Rare Syndrome Resembling Scleroderma: Huriez Syndrome , 2017, Skin Appendage Disorders.
[50] M. Kopeć-Mędrek,et al. Systemic sclerosis sine scleroderma. , 2017, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.
[51] A. Tatu,et al. Bullous Reactions Associated With COX-2 Inhibitors. , 2017, American journal of therapeutics.
[52] A. Tatu,et al. Magistral Prescription With Silver Nitrate and Peru Balsam in Difficult-to-Heal Diabetic Foot Ulcers. , 2017, American journal of therapeutics.
[53] A. Drosos,et al. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. , 2017, Seminars in arthritis and rheumatism.
[54] A. Tatu,et al. CLINICAL, LABORATORY AND THERAPEUTIC PROFILE OF LICHEN PLANUS , 2017 .
[55] C. Georgescu,et al. Pharmacological Principles Used in Patient Monitoring with Type 2 Diabetes , 2017 .
[56] A. Tatu. Umbilicated Blue-Black Lesion on the Lateral Thorax , 2017, Journal of cutaneous medicine and surgery.
[57] R. Monnat,et al. Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions , 2017, Ageing Research Reviews.
[58] I. Lazareth,et al. Paraneoplastic systemic sclerosis: About 3 cases and review of literature. , 2016, Journal des maladies vasculaires.
[59] F. Strollo,et al. Lipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear? , 2016, Diabetes Therapy.
[60] J. Pope,et al. A review of the effects of statins in systemic sclerosis. , 2016, Seminars in arthritis and rheumatism.
[61] V. Vašků,et al. Paraneoplastic Scleroderma: Are There Any Clues? , 2016, Acta dermatovenerologica Croatica : ADC.
[62] Y. Asano. Recent advances in animal models of systemic sclerosis , 2016, The Journal of dermatology.
[63] A. Masi,et al. Progress in the Evolution of Systemic Sclerosis Classification Criteria and Recommendation for Additional Comparative Specificity Studies , 2015, The Journal of Rheumatology.
[64] B. Kahaleh,et al. Endothelial dysfunction in systemic sclerosis , 2014, Current opinion in rheumatology.
[65] S. Hsieh,et al. Rituximab for refractory digital infarcts and ulcers in systemic sclerosis , 2014, Clinical Rheumatology.
[66] J. Simms-Cendán,et al. Clinical recommendation: pediatric lichen sclerosus. , 2014, Journal of pediatric and adolescent gynecology.
[67] D. Huscher,et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group , 2014, Annals of the rheumatic diseases.
[68] Matt Kaeberlein,et al. mTOR Inhibition Alleviates Mitochondrial Disease in a Mouse Model of Leigh Syndrome , 2013, Science.
[69] L. Kumar,et al. Coexistence of scleroderma with multiple myeloma: a rare association , 2013, BMJ Case Reports.
[70] M. Chatterjee,et al. Lyme Borreliosis and Skin , 2013, Indian journal of dermatology.
[71] T. Gambichler,et al. Association of autoimmune diseases with lichen sclerosus in 532 male and female patients. , 2013, Acta dermato-venereologica.
[72] Danwei Huangfu,et al. Human pluripotent stem cells: an emerging model in developmental biology , 2013, Development.
[73] H. Abujudeh,et al. Nephrogenic systemic fibrosis. , 2012, AJR. American journal of roentgenology.
[74] D. Kipling,et al. p38 MAPK stress signalling in replicative senescence in fibroblasts from progeroid and genomic instability syndromes , 2012, Biogerontology.
[75] G. Stingl,et al. Successful treatment of poststreptococcal scleredema adultorum Buschke with intravenous immunoglobulins. , 2012, Archives of dermatology.
[76] A. Caflisch,et al. Phenylalanine assembly into toxic fibrils suggests amyloid etiology in phenylketonuria. , 2012, Nature chemical biology.
[77] N. Lawrentschuk,et al. Penile lichen sclerosus (balanitis xerotica obliterans) , 2011, BJU international.
[78] J. Lazar,et al. A Case of Sclerodermatous Graft‐versus‐Host Disease Responsive to Imatinib Therapy , 2011, Pediatric dermatology.
[79] J. Côté,et al. Eosinophilic Fasciitis: A Rare Skin Sclerosis , 2010, Pathology research international.
[80] P. Merkel,et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. , 2009, Arthritis and rheumatism.
[81] J. Weinreb,et al. Nephrogenic systemic fibrosis. , 2009, Magnetic resonance imaging clinics of North America.
[82] R. Landewé,et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) , 2009, Annals of the rheumatic diseases.
[83] T. Vogt,et al. Safety and tolerability of adjuvant topical tacrolimus treatment in boys with lichen sclerosus: a prospective phase 2 study. , 2008, European urology.
[84] A. Herrick,et al. Raynaud's phenomenon (secondary). , 2008, BMJ clinical evidence.
[85] M. Panesar,et al. Nephrogenic Systemic Fibrosis , 2008, American Journal of Nephrology.
[86] C. Leonetti,et al. Scleroderma-like disorders. , 2008, Autoimmunity reviews.
[87] D. Morrell,et al. Anogenital pruritus: lichen sclerosus in children. , 2007, Pediatric annals.
[88] S. Baithun,et al. Human papillomavirus-associated increase in p16INK4A expression in penile lichen sclerosus and squamous cell carcinoma , 2007, The British journal of dermatology.
[89] N. Hunzelmann,et al. Differential diagnosis of scleroderma and pseudoscleroderma , 2007, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[90] F. Roufosse,et al. SYSTEMIC SCLEROSIS (SCLERODERMA) , 2007, Acta clinica Belgica.
[91] S. Antoniu. Cyclophosphamide for scleroderma interstitial lung disease , 2007, Expert opinion on investigational drugs.
[92] N. Kluger,et al. Syndrome de Werner (progeria de l’adulte) , 2007 .
[93] E. Hachulla,et al. The complexity of managing systemic sclerosis: screening and diagnosis. , 2006, Rheumatology.
[94] T. Gambichler,et al. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. , 2006, Journal of the American Academy of Dermatology.
[95] R. Prayson,et al. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. , 2006, Archives of pathology & laboratory medicine.
[96] Christopher J. Jones,et al. Prevention of accelerated cell aging in Werner syndrome using a p38 mitogen-activated protein kinase inhibitor. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.
[97] G. Webster,et al. Heroic measures may not always be justified in extensive urethral stricture due to lichen sclerosus (balanitis xerotica obliterans). , 2004, Urology.
[98] J. Bridger,et al. Aging of Hutchinson–Gilford progeria syndrome fibroblasts is characterised by hyperproliferation and increased apoptosis , 2004, Experimental Gerontology.
[99] W. Ting,et al. Nephrogenic fibrosing dermopathy with systemic involvement. , 2003, Archives of dermatology.
[100] C. Mok,et al. Scleroderma renal crisis sine scleroderma during pregnancy , 2003, Scandinavian journal of rheumatology.
[101] S. Neill,et al. Guidelines for the management of lichen sclerosus , 2002, The British journal of dermatology.
[102] S. Buechner. Common skin disorders of the penis , 2002, BJU international.
[103] E. Kilbourne,et al. The Spanish toxic oil syndrome 20 years after its onset: a multidisciplinary review of scientific knowledge. , 2002, Environmental health perspectives.
[104] Y. Suga,et al. Two Japanese cases of localized involutional lipoatrophy , 2002, International journal of dermatology.
[105] J. Nava,et al. Scleroderma Renal Crisis Sine Scleroderma , 2001, Nephron.
[106] R. Romiti,et al. Progeria Infantum (Hutchinson–Gilford Syndrome) Associated with Scleroderma‐Like Lesions and Acro‐Osteolysis: A Case Report and Brief Review of the Literature , 2000, Pediatric dermatology.
[107] A. García‐Díez,et al. Lichen sclerosus et atrophicus in sclerodermatous chronic graft‐versus‐host disease , 1999, International journal of dermatology.
[108] F. Wojnarowska,et al. Lichen sclerosus , 1999, The Lancet.
[109] U. Haustein,et al. Drug-induced scleroderma and sclerodermiform conditions. , 1998, Clinics in dermatology.
[110] S. Jablonska,et al. Scleroderma-like disorders. , 1998, Seminars in cutaneous medicine and surgery.
[111] E. Bröcker,et al. The scleroatrophic syndrome of Huriez: a cancer‐prone genodermatosis , 1996, The British journal of dermatology.
[112] G. Saed,et al. Borrelia burgdorferi DNA is undetectable by polymerase chain reaction in skin lesions of morphea, scleroderma, or lichen sclerosus et atrophicus of patients from North America. , 1995, Journal of the American Academy of Dermatology.
[113] Richard W. Martin,et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. , 1995, The Journal of rheumatology.
[114] R. Madhok,et al. Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study. , 1995, Annals of the rheumatic diseases.
[115] K. Cann,et al. Acrodermatitis chronica atrophicans: a case report and review of the literature , 1994, The British journal of dermatology.
[116] S. Buechner,et al. Atrophoderma of Pasini and Pierini. Clinical and histopathologic findings and antibodies to Borrelia burgdorferi in thirty-four patients. , 1994, Journal of the American Academy of Dermatology.
[117] R. Takaki,et al. A case of primary biliary cirrhosis associated with Hashimoto's thyroiditis, scleroderma and Sjögren's syndrome. , 1992, Internal medicine.
[118] I. Téllez,et al. Extracardiac vascular and neural lesions in the toxic oil syndrome. , 1991, Journal of the American College of Cardiology.
[119] M. Tsai,et al. Studies of phenylketonurics with dermatitis. , 1981, Journal of the American Academy of Dermatology.
[120] K. Hashimoto,et al. Acrosclerosis Associated with Vibration: an Electron Microscopic Study , 1980, Journal of cutaneous pathology.
[121] A. Masi. Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.
[122] B. Kwiatkowska-Patzer,et al. [Pseudoscleroderma in a 16-month-old boy with phenylketonuria]. , 1975, Wiadomosci lekarskie.
[123] M. Jänner,et al. [Follicular mucinosis and large area, partly lichenoid, partly sclerodermiform generalized paramyloidosis as a cutaneous paraneoplastic syndrome in myeloma (IgD and light chain plasmacytoma)]. , 1974, Zeitschrift fur Hautkrankheiten.
[124] R. Koch,et al. Phenylketonuria and scleroderma. , 1968, The Journal of pediatrics.
[125] Z. Št̕áva,et al. [Skin manifestations in phenylketonuria. A case with sclerodermiform manifestations]. , 1966, Ceskoslovenska dermatologie.
[126] N. Longo,et al. Phenylketonuria , 1964, Neurology.
[127] L. Czirják,et al. Sclerodermalike syndromes: Great imitators. , 2020, Clinics in dermatology.
[128] A. Tatu,et al. MULTIPLE AUTOIMMUNE SYNDROME TYPE 3- THYROIDITIS,VITILIGO AND ALOPECIA AREATA. , 2017, Acta endocrinologica.
[129] A. Herrick,et al. Digital ulcers in systemic sclerosis , 2017, Rheumatology.
[130] C. Denton. Advances in pathogenesis and treatment of systemic sclerosis. , 2016, Clinical medicine.
[131] L. Hummers,et al. Scleroderma Mimickers , 2016, Current Treatment Options in Rheumatology.
[132] J. D. da Silva,et al. Paraneoplastic sclerodermiform syndrome--case report. , 2014, Acta reumatologica portuguesa.
[133] K. Becker. Lichen sclerosus in boys. , 2011, Deutsches Arzteblatt international.
[134] A. Cuvelier,et al. [Paraneoplastic sclerodermiform syndrome]. , 2010, Revue des maladies respiratoires.
[135] M. Seyger,et al. Efficacy of Topical Tacrolimus 0.1% in Active Plaque Morphea , 2009, American journal of clinical dermatology.
[136] P. Bale,et al. Balanitis xerotica obliterans in children. , 1987, Pediatric pathology.
[137] F. Cambazard,et al. [Pseudoscleroderma and sclerodermiform states]. , 1984, Annales de medecine interne.
[138] Z. Kraus. Acrodermatitis chronica atrophicans. , 1970, Sbornik vedeckych praci Lekarske fakulty Karlovy university v Hradci Kralove.